Resources
4 Results (showing 1 - 4)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/1/2021 (updated 4/5/2024)
This webinar will provide an overview of COVID-19 impacts and vaccination attitudes among SUD populations in Vermont including people who use drugs, patients receiving MAT, and people in recovery. It will outline the methods undertaken to conduct a community-based survey. It will discuss the barriers and opportunities that arose from analysis of the survey and a subsequent consortium workshop.
Posted 12/15/2020 (updated 4/3/2024)
Dr. Seale led a discussion on communicating OUD needs in your community, building MOUD practice capacity, and other considerations and lessons learned from his work with individuals in rural communities.
Posted 6/2/2020 (updated 3/28/2024)
We know from RCORP grantees, first responders, hospitals, people who use drugs, the media and other allies that many communities are seeing spikes in overdose (OD) events and deaths since the onset of COVID-19. Sometimes these deaths come at alarming levels because of stretched public health infrastructure and the time it takes to turn around data. The webinar took place on May 26, 2020.
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs